DNA methylation biomarkers predict progression-free and overall survival of metastatic renal cell cancer (mRCC) treated with antiangiogenic therapies

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Peters, Inga ^a   Dubrowinskaja, Natalia ^a   Abbas, Mahmoud ^a   Seidel, Christoph ^b   Kogosov, Michael ^a   Scherer, Ralph ^a   Gebauer, Kai ^a   Merseburger, Axel S ^a   Kuczyk, Markus A ^a   Grünwald, Viktor ^a   Serth, Jürgen ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; BEVACIZUMAB; CYSTATIN M; SORAFENIB; SUNITINIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; CLINICAL ARTICLE; CPG ISLAND; CST6 GENE; DNA METHYLATION; FEMALE; GENE; HSA MIR 124 3 GENE; HSA MIR 9 1 GENE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY METASTASIS; LAD1 GENE; MALE; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PREDICTION; PROGRESSION FREE SURVIVAL; SENSITIVITY AND SPECIFICITY; VERY ELDERLY; CANCER STAGING; CARCINOMA, RENAL CELL; CLUSTER ANALYSIS; GENETICS; METASTASIS; MORTALITY; PATHOLOGY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLUSTER ANALYSIS; DNA METHYLATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; ROC CURVE; TREATMENT OUTCOME;

EID: 84898494234     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091440     Document Type: Article

References (31)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin. 2011/02/08 ed.
2. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, et al. (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584-3590.
3. Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, et al. (2013) A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update. European journal of cancer 49: 1287-1296.
4. Skolarikos AA, Papatsoris AG, Alivizatos G, Deliveliotis C (2006) Molecular pathogenetics of renal cancer. Am J Nephrol 26: 218-231. (Pubitemid 44121090)
5. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, et al. (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22: 454-463. (Pubitemid 41079774)
6. Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, et al. (2013) External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. The lancet oncology 14: 141-148.
7. Galsky MD (2013) A prognostic model for metastatic renal-cell carcinoma. Lancet Oncol 14: 102-103.
8. Nickerson P (2008) The impact of immune gene polymorphisms in kidney and liver transplantation. Clinics in laboratory medicine 28: 455-468, vii.
9. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, et al. (2010) Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463: 360-363.
10. Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, et al. (2008) von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 180: 860-865; discussion 865-866.
11. Garcia-Donas J, Esteban E, Leandro-Garcia LJ, Castellano DE, del Alba AG, et al. (2011) Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol 12: 1143-1150.
12. Gigante M, Li G, Ferlay C, Perol D, Blanc E, et al. (2012) Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapy. Anticancer Res 32: 5447-5451.
13. Sun M, Shariat SF, Cheng C, Ficarra V, Murai M, et al. (2011) Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol 60: 644-661.
14. Varela I, Tarpey P, Raine K, Huang D, Ong CK, et al. (2011) Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469: 539-542.
15. Baldewijns MM, van Vlodrop IJ, Schouten LJ, Soetekouw PM, de Bruine AP, et al. (2008) Genetics and epigenetics of renal cell cancer. Biochim Biophys Acta 1785: 133-155.
16. Vanharanta S, Shu W, Brenet F, Hakimi AA, Heguy A, et al. (2013) Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Nat Med 19: 50-56.
17. Larkin J, Goh XY, Vetter M, Pickering L, Swanton C (2012) Epigenetic regulation in RCC: opportunities for therapeutic intervention? Nat Rev Urol 9: 147-155.
18. Morris MR, Hesson LB, Wagner KJ, Morgan NV, Astuti D, et al. (2003) Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma. Oncogene 22: 6794-6801. (Pubitemid 37372219)
19. Morris MR, Ricketts C, Gentle D, Abdulrahman M, Clarke N, et al. (2010) Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene 30: 1390-1401.
20. van Vlodrop IJ, Baldewijns MM, Smits KM, Schouten LJ, van Neste L, et al. (2010) Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma. Am J Pathol 176: 575-584.
21. Gebauer K, Peters I, Dubrowinskaja N, Hennenlotter J, Abbas M, et al. (2013) Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma. Br J Cancer 108: 131-138.
22. Hildebrandt MA, Gu J, Lin J, Ye Y, Tan W, et al. (2010) Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene 29: 5724-5728.
23. Motoki K, Megahed M, LaForgia S, Uitto J (1997) Cloning and chromosomal mapping of mouse ladinin, a novel basement membrane zone component. Genomics 39: 323-330. (Pubitemid 27078698)
24. Sohaib A (2012) RECIST rules. Cancer imaging : the official publication of the International Cancer Imaging Society 12: 345-346.
25. Sobin LH, Compton CC (2010) TNM seventh edition: what's new, what's changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer. Cancer 116: 5336-5339.
26. NCI National Cancer Institute Dictionary of Cancer Terms.
27. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, et al. (2002) The human genome browser at UCSC. Genome Res 12: 996-1006. (Pubitemid 34662293)
28. Weisenberger DJ, Campan M, Long TI, Kim M, Woods C, et al. (2005) Analysis of repetitive element DNA methylation by MethyLight. Nucleic acids research 33: 6823-6836. (Pubitemid 41830488)
29. Seidel C, Busch J, Weikert S, Steffens S, Fenner M, et al. (2012) Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma. Eur J Cancer 48: 1023-1030.
30. Team RDC (2011) R: A language and environment for statistical computing R Foundation for Statistical Computing: Vienna, Austria.
31. Knox JJ (2008) Progression-free survival as endpoint in metastatic RCC? Lancet 372: 427-429.